Ardelyx (ARDX) shares surged approximately 8% following news of price hikes for its main products, tenapanor, branded as Ibsrela and Xphozah. Effective January 1, 2026, Ibsrela's price increased by 9% and Xphozah's by 8%, surpassing last year's hikes of 5% and 7%, respectively. Analyst Christopher Raymond from Raymond James, who maintains a Strong Buy rating on ARDX, noted the price adjustments are more aggressive than in previous years, potentially supporting the company's commercial strategy. Ardelyx reported net sales of $158.3M for Ibsrela and $160.9M for Xphozah in 2024.
https://www.gurufocus.com/news/4092670/ardelyx-ardx-boosts-product-prices-shares-climb
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.